CLINICAL_TRIALS
research
· 2025-12-12
Clinical Trial Update: Immunogenicity of RSVPreF3 Vaccine in Immunocompromised Persons [Phase 2]
Summary
A Phase 2 clinical trial is evaluating the immunogenicity of the RSVPreF3 vaccine in immunocompromised adults, with recruitment ongoing.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Johns Hopkins University | Conditions: Respiratory Syncytial Virus (RSV) | Phase 2 | Status: RECRUITING